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Cost-effectiveness of an Ineffective Therapy(?)
In the June issue of the Journal, Pedretti et al. (1) presented
an innovative study on the cost-effectiveness of different
tests to select postinfarct patients for amiodarone therapy.
However, as the accompanying editorial (2) pointed out, the
“cost-effectiveness of these tests can be no better than the
cost-effectiveness of the therapies prescribed based on their
results.” To this end, I think the conclusion reached in this
paper is weak and may be misleading for readers of this
journal.
Amiodarone has not been shown to improve overall
survival in post-MI patients. Only a meta-analysis (3),
which has important limitations, suggests a possible benefit.
The analyses in the present study relied entirely on the data
from EMIAT and CAMIAT trials, which did not show an
overall improvement in survival. No tests can be cost-
effective if the treatment selected is not. Using amiodarone
as a sole therapy in this high-risk group of patients,
especially those with a positive EP study, is clinically
unrealistic and renders the accompanying analyses irrele-
vant.
On the other hand, implantable defibrillators (ICDs)
have been shown to improve overall survival in two pub-
lished (MADIT and AVID) (4,5) and two unpublished
(CIDS and CASH) prospective randomized controlled
trials. Unfortunately, the use of ICDs as an alternative to
amiodarone was not emphasized by Pedretti et al. (1) or in
the accompanying editorial (2). Had the authors included
this proven therapy as a treatment option in their study,
invasive strategy with EP studies may turn out to be
cost-effective simply because of the effectiveness of ICD and
its superiority over amiodarone (4,5).
The conclusions reached by Pedretti et al. (1) at best
provide little clinically useful information and at worst are
potentially misleading. Because an inferior treatment was
chosen for analysis, it is not surprising that invasive electro-
physiology studies did not prove to be cost-effective. By
omitting to include ICDs as a treatment option and by
failing to discuss this important limitation, this study does
the readers of this journal a disservice by undermining the
true utility of electrophysiology studies in selecting patients
for appropriate treatment (4). I believe that the publication
of this paper, sets us back a full decade in our practice of
clinical electrophysiology.
James J. C. Ong, MD, FACC, FCCP
Tarzan, California
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REPLY
Dr Ong expressed some criticism concerning our recent
paper (1).
Results of base-case analysis showed that amiodarone
improved survival in recent post-MI patients with low heart
rate variability at an incremental cost between $20,000 and
$40,000/additional QALY which is consistent with other
currently founded programs, such as hemodialysis or treat-
ment of mild hypertension with diuretic drugs or propran-
olol. In our model, this acceptable incremental cost-
effectiveness ratio derived from a 17% amiodarone-induced
reduction in total mortality at two years, which is similar to
the significant survival benefit observed in a recent pub-
lished meta-analysis (2). Sensitivity analysis showed similar
cost-effectiveness ratios in other subgroups of patients
selected by different noninvasive testing, but not in those
with CAMIAT and EMIAT screening criteria. These data
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